Videos

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the role of the first FDA-approved biosimilar epoetin alfa in cancer care.

Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, explains what he sees as the main challenges with incorporating biosimilars in the cancer clinic.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes current educational needs around biosimilars.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes the biosimilar approval pathway in the United States.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses experience with biosimilar pegfilgrastim so far.

Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, discusses his research that showed that the incidence of febrile neutropenia was similar between patients who received reference filgrastim versus those who received a biosimilar.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the European experience with using nonproprietary names for biosimilar pharmacovigilance.

Anton Franken, MD, PhD, endocrinologist, discusses how to communicate with patients who are going to be switched to biosimilar insulin.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), explains how a recent trade deal could take a toll on biosimilars.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses how the FDA plans to address citizen petitions that impede market entry of competitive products.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the FDA’s recent guidance on the naming of biosimilars, biologics, and interchangeable products.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, describes imporant considerations in preparing for the arrival of biosimilar rituximab.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes early experience with biosimilar adalimumab in Europe.

Beata Ambroziewicz, president of the Polish Union of Patient Organizations and board member of the Polish Cancer Patient Coalition, discusses patients' concerns about biosimilars and the need for more education about switching.

Anton Franken, MD, PhD, endocrinologist, discusses how closely patients who switch to biosimilars must be monitored.

Carol Lynch, president of Sandoz US and head of North America, discusses the FDA's role in instilling confidence in biosimilars.

Carol Lynch, president of Sandoz US and head of North America, discusses the promise of the US biosimilars market.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses state laws targeting drug prices.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), explains the role of patents in delays to US adalimumab biosimilar launches.

Carol Lynch, president of Sandoz US and head of North America, discusses which stakeholders have a role in addressing misinformation about biosimilars.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses the state of biosimilar regulation in the United States.

Carol Lynch, president of Sandoz US and head of North America, discusses the barriers blocking market access for biosimilars in the United States.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), discusses how to address high US drug prices.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), discusses AbbVie's patents on the innovator adalimumab, Humira.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses recent congressional interest in drug pricing.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses HHS’ proposal to require that drugs’ list prices appear in direct-to-consumer advertising.